The DOI matches its Crossref record; 87 of the 89 references it cites were found in a registry or an index.
Omega-3 Fatty Acid Formulations in Cardiovascular Disease: Dietary Supplements are Not Substitutes for Prescription Products
Open accessAbstract
Omega-3 fatty acid products are available as prescription formulations (icosapent ethyl, omega-3-acid ethyl esters, omega-3-acid ethyl esters A, omega-3-carboxylic acids) and dietary supplements (predominantly fish oils). Most dietary supplements and all but one prescription formulation contain mixtures of the omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Products containing both EPA and DHA may raise low-density lipoprotein cholesterol (LDL-C). In clinical trials, the EPA-only prescription product, icosapent ethyl, did not raise LDL-C compared with placebo. To correct a common misconception, it is important to note that omega-3 fatty acid dietary supplements are not US FDA-approved over-the-counter drugs and are not required to demonstrate safety and efficacy prior to marketing. Conversely, prescription products are supported by extensive clinical safety and efficacy investigations required for FDA approval and have active and ongoing safety monitoring programs. While omega-3 fatty acid dietary supplements may have a place in the supplementation of diet, they generally contain lower levels of EPA and DHA than prescription products and are not approved or intended to treat disease. Perhaps due to the lack of regulation of dietary supplements, EPA and DHA levels may vary widely within and between brands, and products may also contain unwanted cholesterol or fats or potentially harmful components, including toxins and oxidized fatty acids. Accordingly, omega-3 fatty acid dietary supplements should not be substituted for prescription products. Similarly, prescription products containing DHA and EPA should not be substituted for the EPA-only prescription product, as DHA may raise LDL-C and thereby complicate the management of patients with dyslipidemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Structures of omega-3 fatty acids. Both omega-6 and omega-3 fatty acids are polyunsaturated fatty acids, meaning that the hydrocarbon chain contains multiple double bonds. The naming convention is [number of carbon atoms]:[number of double bonds], n- (or ω)-[position of first double bond starting from the methyl end of the chain, shown in red]. Omega-3 fatty acids generally have anti-inflammatory and anti-thrombotic properties, whereas omega-6 fatty acids generally have pro-inflammatory and pro-thrombotic properties](https://figures.cochat.ai/paper-figures/fa4fb9abe67a4a29bd4d25a9f0665aea/omega-3-fatty-acid-formulations-in-cardiovascular-disease-dietary-supplements-figure-1.jpg)

![Fig. 3 Percentage change from baseline versus placebo in key lipid parameters from clinical trials of prescription omega-3 fatty acid products (4 g/day) in patients with very high triglycerides (≥500 mg/dl) [48–50, 54]. Upper limit for triglycerides was 2000 mg/dl in studies of omega-3-acid ethyl esters, omega-3-carboxylic acids, and icosapent ethyl and 1500 mg in the omega-3-acid ethyl esters A study. Omega-3-acid ethyl esters values are based on pooled data from two studies [10, 11] (6 and 16 weeks’ duration) as reported in the omega-3-acid ethyl esters prescribing information [48]. Icosapent ethyl data are from the MARINE (Multi-Center, Placebo-Controlled, Randomized, Double-Blind, 12-Week Study with an Open-Label Extension) study (12 weeks) [12]. Omega-3-acid ethyl esters A data (12 weeks) have only been published in the product’s prescribing information [49]. Omega-3-carboxylic acids data are from the EVOLVE (Epanova for Lowering Very High Triglycerides) study (12 weeks) [13]. Difference versus placebo: omega-3-acid ethyl esters = omega-3-acid ethyl esters median % change—placebo median % change; icosapent ethyl = median of [icosapent ethyl % change—placebo % change] (Hodges–Lehmann estimate); omega-3-acid ethyl esters A = Hodges–Lehmann median of all pairwise differences from placebo; omega-3-carboxylic acids = median of [omega-3-carboxylic acids % change—placebo % change] (Hodges–Lehmann estimate). HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, TC total cholesterol, TG triglycerides](https://figures.cochat.ai/paper-figures/e7eb67e0a6f348d0a96055fb267f6224/omega-3-fatty-acid-formulations-in-cardiovascular-disease-dietary-supplements-figure-3.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Although OM-3 dietary supplements are available, there are no Food and Drug Administration (FDA)-approved over-the-counter (OTC) OM-3 medications in the USA.”
From Critical Differences Between Dietary Supplement and Prescription Omega-3 Fatty Acids: A Narrative Review (2020) · cites this paper as [7]
The cited source says what the claim attributes to it.
In the citing paper
“Currently available OM-3 products in the US are either prescription (Rx) medications or non-Rx OM-3 dietary supplements (e.g., fish oils) [7].”
From Critical Differences Between Dietary Supplement and Prescription Omega-3 Fatty Acids: A Narrative Review (2020) · cites this paper as [7]
In the citing paper
“Patients and health care providers may mistakenly believe that dietary supplements are OTC medications [7].”
From Critical Differences Between Dietary Supplement and Prescription Omega-3 Fatty Acids: A Narrative Review (2020) · cites this paper as [7]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Standards of Medical Care in Diabetes
Power, D. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1593 · Cited by 8,673
Inflammation in atherosclerosis
Libby, P. (2002) · Nature · doi:10.1038/nature01323 · Cited by 8,315
Inflammation and Atherosclerosis
Libby, P., Ridker, P. M., & Maseri, A. (2002) · Circulation · doi:10.1161/hc0902.104353 · Cited by 7,724
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
(1999) · The Lancet · doi:10.1016/s0140-6736(99)07072-5 · Cited by 3,812 · cited 1×
“Some trials showed significant improvements in clinical outcomes [81, 86, 87], whereas others did not [88–91].”
ResultInflammation in Atherosclerosis
Libby, P. (2012) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.108.179705 · Cited by 3,736
Yokoyama, M., Origasa, H., Matsuzaki, M., Matsuzawa, Y., Saito, Y., Ishikawa, Y., Oikawa, S., Sasaki, J., Hishida, H., Itakura, H., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60527-3 · Cited by 2,516 · cited 1×
“Some trials showed significant improvements in clinical outcomes [81, 86, 87], whereas others did not [88–91].”
ResultEfficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Robinson, J. G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., Stroes, E. S., Langslet, G., Raal, F. J., El Shahawy, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501031 · Cited by 2,296 · cited 1×
“More recently, clinical trials of ezetimibe (IMPROVE-IT [82]) and proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors (OSLER study [83] and ODYSSEY LONG TERM study [84]) have confirmed or suggested that statin add-on therapy may be effective in further reducing residual cardiovascular risk.”
Background(1999) · PubMed · Cited by 2,062
EICOSAPENTAENOIC ACID AND PREVENTION OF THROMBOSIS AND ATHEROSCLEROSIS?
DYERBERG, J. (1978) · The Lancet · doi:10.1016/s0140-6736(78)91505-2 · Cited by 1,688
Research works printed but not linked: 4
- Niki T, Wakatsuki T, Bando M, et al. Effects of additional eicosapentaenoic acid to statin therapy on inflammatory cytokines and the tissue characterization of coronary plaque assessed by integrated backscatter intravascular ultrasound systems [abstract 14434]. Circulation. 2012;126(21 Suppl.):14434.
- Katoh A, Ikeda H. Daily intake of eicosapentaenoic acid inhibits the progression of carotid intimal-media thickness in patients with dyslipidemia [in Japanese]. Ther Res. 2011;32(6):863–8.
- Truong P, Johnson C, Gabriel D. Variability of cholesterol and saturated fat content in dietary supplements [abstract P72]. Circulation. 2007;115(8):e238.
- Lopez JAG, Ito MK. PLA chapter update: prescription fish oil and Blue Cross of Idaho. LipidSpin. 2010;8(3):32–4.
Cited by
Serhan, C. N. (2017) · The FASEB Journal · doi:10.1096/fj.201601222r · Cited by 555
“It is clear that dietary supplements containing the n-3 fatty acids, precursors to the Rvs, PDs and MaRs, are not substitutes for prescription drugs (134).”
BackgroundSkulas-Ray, A. C., Wilson, P. W. F., Harris, W. S., Brinton, E. A., Kris-Etherton, P. M., Richter, C. K., Jacobson, T. A., Engler, M. B., Miller, M., Robinson, J. G., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000709 · Cited by 512
Dietary Polyunsaturated Fatty Acids (PUFAs): Uses and Potential Health Benefits
Kapoor, B., Kapoor, D., Gautam, S., Singh, R., & Bhardwaj, S. (2021) · Current Nutrition Reports · doi:10.1007/s13668-021-00363-3 · Cited by 418
A Comprehensive Review of Chemistry, Sources and Bioavailability of Omega-3 Fatty Acids
Cholewski, M., Tomczykowa, M., & Tomczyk, M. (2018) · Nutrients · doi:10.3390/nu10111662 · Cited by 372
“This is due to the fact that the food of many fish are algae rich in EPA and DHA, and other organisms consuming algae, like fish or marine invertebrates [136,137].”
BackgroundInfluentialPPAR Agonists and Metabolic Syndrome: An Established Role?
Botta, M., Audano, M., Sahebkar, A., Sirtori, C., Mitro, N., & Ruscica, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19041197 · Cited by 253
“Apparently, products containing DHA may increase LDL-C levels, whereas those containing EPA only products do not lead to a similar consequence [104,105].”
Background
Metadata
- Authors
- Fialkow, J.
- Affiliations
- Baptist Hospital of Miami (US)
- Corresponding author
- Fialkow, Jonathan
- Venue
- American Journal of Cardiovascular Drugs
- Published
- 2016-04-30
- Volume
- 16
- Issue
- 4
- Pages
- 229-239
- ISSN
- 1175-3277 (ISSN-L)
- 1179-187X
- PMC
- PMC4947114
- OpenAlex
- W2345135102
- Cited by
- 80
- References
- 89
- Citations by year
- 2026: 7 · 2025: 4 · 2024: 5 · 2023: 20 · 2022: 7 · 2021: 6 · 2020: 7 · 2019: 9 · 2018: 6 · 2017: 6 · 2016: 1
- FWCI
- 0.98
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- American Journal of Cardiovascular Drugs (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Scholarly Commons - Baptist Health South Florida (Baptist Health South Florida) (submittedVersion)
- Funders
- Amarin Corporation
- Amarin Pharma
- Topics
- Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Complementary and alternative medicine › Complementary and Alternative Medicine Studies
- Keywords
- omega-3 fatty acids, icosapent ethyl, omega-3 acid ethyl esters, dietary supplements, fish oil, eicosapentaenoic acid, docosahexaenoic acid, LDL cholesterol, dyslipidemia, cardiovascular disease, FDA regulation of dietary supplements, oxidized fatty acids
- MeSH terms
- Animals, Hypolipidemic Agents, Cardiovascular Diseases, Chemistry, Pharmaceutical, Diet, Docosahexaenoic Acids, Humans, Cholesterol, LDL, Eicosapentaenoic Acid, Hypertriglyceridemia, Fatty Acids, Omega-3, Dietary Supplements, Dyslipidemias, Prescription Drugs
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Omega-3 Fatty Acid Formulations in Cardiovascular Disease: Dietary Supplements are Not Substitutes for Prescription Products. https://app.cochat.ai/papers/10.1007/s40256-016-0170-7
- The paper
- Fialkow, J. (2016). Omega-3 Fatty Acid Formulations in Cardiovascular Disease: Dietary Supplements are Not Substitutes for Prescription Products. American Journal of Cardiovascular Drugs. https://doi.org/10.1007/s40256-016-0170-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.